Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Polypyrimidine tract-binding protein 3 (PTBP3)
- Target
- PTBP3
- Molecular classification
- RNA-binding protein, Heterogeneous nuclear ribonucleoprotein (hnRNP) family, Post-transcriptional regulator
01
Overview
Polypyrimidine tract-binding protein 3 (PTBP3) is an RNA-binding protein of the hnRNP family that binds to CU-rich elements in exons and introns, influencing mRNA splicing, stability, localization, and translation. It is crucial for regulating cell differentiation and post-transcriptional gene expression. PTBP3 is highly expressed in many cancers and is associated with poor prognosis, cancer progression, metastasis, and resistance to chemotherapy. Mechanistically, PTBP3 controls key cancer-related processes such as epithelial–mesenchymal transition, cell migration, and tumor microenvironment interactions. Functionally, PTBP3 can be used as a biomarker for predicting cancer outcomes and may represent a therapeutic target, although intervention carries uncertainties due to its extensive involvement in essential cellular processes.
- Other names
- PTBP3ROD1Regulator of differentiation 1DKFZp781I1117
02
Mechanism of action
Drugs that interact with PTBP3 may target its post-transcriptional regulatory roles, such as modulating splicing, mRNA stability, or translation to inhibit tumor growth, metastasis, or therapy resistance
03
Biological functions
Regulation of alternative splicingControl of mRNA stabilityRegulation of mRNA localizationModulation of mRNA translationCell differentiation regulatorControl of cell cycle and migration
04
Disease associations
Cancer (implicated in breast, colon, pancreatic, gastric, lung, and uterine cancers)TumorigenesisCancer metastasisPoor prognosis markerTherapy resistance (e.g., pancreatic cancer and gemcitabine resistance)
05
Safety considerations
Therapeutic targeting may impact global RNA processing, affecting normal cell differentiation and functionPotential for off-target effects due to widespread roles in RNA metabolism
06
Interacting drugs
Gemcitabine
07
Biomarkers
PTBP3 expression levels (high expression correlates with poor prognosis in several cancers)Phosphorylation at S30 and S426 sites (associated with tumor tissues)PTBP3-related immune infiltration markers (correlation with tumor-associated fibroblasts and immune checkpoints)
Beyond the preview
Go deeper on Polypyrimidine tract-binding protein 3 (PTBP3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Polypyrimidine tract-binding protein 3 (PTBP3).